C

Cellectis SA
D

CLLS

1.54000
USD
0.05
(3.36%)
Market Closed
Volume
9,850
EPS
-1
Div Yield
-
P/E
-1
Market Cap
154,144,564
OverviewSignalsIdeasNews
Related Instruments
    A
    ALLO
    0.08000
    (4.34%)
    1.92500 USD
    B
    BEAM
    1.860
    (7.59%)
    26.380 USD
    B
    BLUE
    -0.31000
    (-3.79%)
    7.86000 USD
    C
    CRSP
    2.740
    (6.61%)
    44.200 USD
    E
    EDIT
    0.15000
    (12.50%)
    1.35000 USD
    F
    FATE
    0.03000
    (2.28%)
    1.34500 USD
    GILD
    GILD
    0.070
    (0.08%)
    93.020 USD
    N
    NTLA
    1.040
    (10.45%)
    10.990 USD
    VRTX
    VRTX
    0.08
    (0.02%)
    428.09 USD
    More
News

Title: Cellectis SA

Sector: Healthcare
Industry: Biotechnology
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.
Trading. Social. Simple.
FacebookTwitterYoutube
Company
Contact usAbout usTerms Of UsePrivacy PolicyCookies PolicyDisclaimerHelp Center
Social Network
The NetworkSignals NetworkIdeas NetworkBest Traders
Products
Risk CalculatorPip CalculatorAdvance Chart
Markets
Exchange RatesCommodities RatesCryptocurrencies RatesIndices RatesUS Stocks Rates
Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.